HIFU is a new, FDA-approved procedure performed at Stanford Health Care. It is still, however, considered experimental as U.S. physicians continue to gather data. The procedure has been available in Europe for more than 10 years, with promising results with respect to cancer control and side effects. As with all tissue-sparing therapies, including HIFU, there is a risk of recurrence since the entire prostate gland is not treated.  This may require re-treatment with HIFU or another form of prostate cancer treatment, such as surgery or radiation therapy.